That is impressive growth in sales AND prescribers, especially if you model out. The sell side analysts will eventually figure this out and re-engage in Ariad. It won't take much to launch this as long as the market doesn't tank.. This company is so unloved and undesired, which makes it a buy...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.